I am a
Home I AM A Search Login

Papers of the Week

2022 Oct-Dec

Acta Gastroenterol Belg



Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.


Deprez N, De Somer T, Baert D, Deceuninck M, Huys I, Mattens V, Sterckx A, Vanderstraeten E, Vandervoort J, Van Heddegem N, Dewint P
Acta Gastroenterol Belg. 2022 Oct-Dec; 85(4):557-564.
PMID: 36566364.


Prospective data are lacking on evolution of trough levels, effectiveness, acceptance rate and patient satisfaction after switch from the adalimumab originator to a biosimilar in patients with inflammatory bowel disease.